Literature DB >> 34555865

Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet versus traditional dietary advice for functional dyspepsia: a randomized controlled trial.

Omesh Goyal1, Sahil Nohria1, Shaveta Batta2, Armaan Dhaliwal3, Prerna Goyal4, Ajit Sood1.   

Abstract

BACKGROUND AND AIM: Prospective trials evaluating efficacy of specific diet restriction in functional dyspepsia (FD) are scarce. We aimed to assess efficacy of low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet in FD, compared with traditional dietary advice (TDA).
METHODS: In this prospective, single-blind trial, patients with FD (Rome IV) were randomized into low FODMAP diet (LFD) and TDA groups, for 4 weeks (phase I). In phase II (4-12 weeks), LFD group was advised systematic re-introduction of FODMAPs. Symptom severity and quality of life were assessed using "Short-Form Nepean Dyspepsia Index (SF-NDI)." Primary outcome was symptomatic response (symptom score reduction of ≥ 50%), at 4 weeks. Study was registered with CTRI (2019/06/019852).
RESULTS: Of 184 patients screened, 105 were randomized to LFD (n = 54) and TDA (n = 51) groups. At 4 weeks, both groups showed significant reduction in SF-NDI symptom scores compared with baseline, with no significant difference in inter-group response rates [LFD: 66.7% (36/54); TDA: 56.9% (29/51); P = 0.32]. On sub-group analysis, patients with postprandial distress syndrome or bloating had significantly better symptomatic response with LFD (P = 0.04). SF-NDI quality of life scores improved significantly in both groups. On multivariate analysis, factors predicting response to LFD were bloating and male gender. Incidences of adverse events (minor) were similar in both groups.
CONCLUSIONS: In patients with FD, LFD and TDA lead to significant symptomatic and quality of life improvement. Patients with postprandial distress syndrome or bloating respond significantly better to LFD. Therefore, dietary advice for FD should be individualized according to FD subtype.
© 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  bloating; disorders of gut-brain interaction; epigastric pain syndrome; functional gastro-intestinal disorder; post-prandial distress syndrome

Mesh:

Substances:

Year:  2021        PMID: 34555865     DOI: 10.1111/jgh.15694

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  Author's reply to comment on the article: Psychological issues in patients with irritable bowel syndrome: Throwing more light is necessary.

Authors:  Omesh Goyal; Sahil Nohria; Armaan Singh Dhaliwal; Prerna Goyal; Ravinder Kumar Soni; Rajoo Singh Chhina; Ajit Sood
Journal:  Indian J Gastroenterol       Date:  2021-12

2.  British Society of Gastroenterology guidelines on the management of functional dyspepsia.

Authors:  Christopher J Black; Peter A Paine; Anurag Agrawal; Imran Aziz; Maria P Eugenicos; Lesley A Houghton; Pali Hungin; Ross Overshott; Dipesh H Vasant; Sheryl Rudd; Richard C Winning; Maura Corsetti; Alexander C Ford
Journal:  Gut       Date:  2022-07-07       Impact factor: 31.793

3.  Exclusion Diets in Functional Dyspepsia.

Authors:  Stefan Lucian Popa; Dinu Iuliu Dumitrascu; Cristina Pop; Teodora Surdea-Blaga; Abdulrahman Ismaiel; Giuseppe Chiarioni; Dan Lucian Dumitrascu; Vlad Dumitru Brata; Simona Grad
Journal:  Nutrients       Date:  2022-05-14       Impact factor: 6.706

4.  Quality of life in Indian patients with functional dyspepsia: Translation and validation of the Hindi version of Short-Form Nepean Dyspepsia Index.

Authors:  Omesh Goyal; Prerna Goyal; Harsh Kishore; Jaskirat Kaur; Paraag Kumar; Ajit Sood
Journal:  Indian J Gastroenterol       Date:  2022-02-21

Review 5.  Evidence-Based and Emerging Dietary Approaches to Upper Disorders of Gut-Brain Interaction.

Authors:  Jan Tack; Hans Tornblom; Victoria Tan; Florencia Carbone
Journal:  Am J Gastroenterol       Date:  2022-04-13       Impact factor: 12.045

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.